Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

Article  PubMed  CAS  Google Scholar 

Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181–90. https://doi.org/10.1200/JCO.2009.26.2543.

Article  PubMed  CAS  Google Scholar 

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919–29. https://doi.org/10.1056/NEJMoa1709937.

Article  PubMed  CAS  Google Scholar 

Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022;40(12):1301–11. https://doi.org/10.1200/JCO.21.01308.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lau SWJ, Huang Y, Hsieh J, Wang S, Liu Q, Slattum PW, et al. Participation of older adults in clinical trials for new drug applications and biologics license applications from 2010 through 2019. JAMA Netw Open. 2022;5(10): e2236149. https://doi.org/10.1001/jamanetworkopen.2022.36149.

Article  PubMed  PubMed Central  Google Scholar 

Statistics Canada. Lung cancer is the leading cause of cancer death in Canada. Ottawa, Canada: Government of Canada; 2022 [accessed 6 June 2024]. Available at: https://www.statcan.gc.ca/o1/en/plus/238-lung-cancer-leading-cause-cancer-death-canada

Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, et al. Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study. J Thorac Oncol. 2023;18(2):181–93. https://doi.org/10.1016/j.jtho.2022.10.003.

Article  PubMed  CAS  Google Scholar 

Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452–60. https://doi.org/10.1093/jnci/djr325.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Catania C, Filippi AR, Sangalli C, Piperno G, Russano M, Greco C, et al. New options and open issues in the management of unresectable stage III and in early-stage NSCLC: a report from an expert panel of Italian medical and radiation oncologists—INTERACTION group. Crit Rev Oncol Hematol. 2023;190: 104108. https://doi.org/10.1016/j.critrevonc.2023.104108.

Article  PubMed  Google Scholar 

Jaiyesimi IA, Leighl NB, Ismaila N, Alluri K, Florez N, Gadgeel S, et al. Therapy for stage IV non-small cell lung cancer without driver alterations: ASCO living guideline, version 2023.3. J Clin Oncol. 2024;42(11):e23–43. https://doi.org/10.1200/JCO.23.02746.

Article  PubMed  Google Scholar 

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33. https://doi.org/10.1056/NEJMoa1606774.

Article  PubMed  CAS  Google Scholar 

Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, Dómine M, et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol. 2023;41(11):1992–8. https://doi.org/10.1200/JCO.22.01989.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Novello S, Kowalski DM, Luft A, Gümüş M, Vicente D, Mazières J, et al. Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study. J Clin Oncol. 2023;41(11):1999–2006. https://doi.org/10.1200/JCO.22.01990.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Amin MB, Edge SB, Greene FL, et al editors. AJCC cancer staging manual. 8th ed. New York: Springer; 2017.

Google Scholar 

Bryant AK, Sankar K, Strohbehn GW, Zhao L, Elliott D, Qin A, et al. Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer. Lung Cancer. 2022;163:35–41. https://doi.org/10.1016/j.lungcan.2021.11.021.

Article  PubMed  CAS  Google Scholar 

Stevens S, Nindra U, Shahnam A, Wei J, Bray V, Pal A, et al. Real world efficacy and toxicity of consolidation durvalumab following chemoradiotherapy in older Australian patients with unresectable stage III non-small cell lung cancer. J Geriatr Oncol. 2024;15(2): 101705. https://doi.org/10.1016/j.jgo.2024.101705.

Article  PubMed  CAS  Google Scholar 

Park JE, Hong KS, Choi SH, Lee SY, Shin KC, Jang JG, et al. Durvalumab consolidation after chemoradiotherapy in elderly patients with unresectable stage III NSCLC: a real-world multicenter study. Clin Lung Cancer. 2024;25(4):354–64. https://doi.org/10.1016/j.cllc.2024.02.006.

Article  PubMed  CAS  Google Scholar 

Surveillance, Epidemiology, and End Results Program. Lung and bronchus cancer—Cancer stat facts. United States: National Cancer Institute; 2020 [accessed on 9 June 2024]. Available at: https://seer.cancer.gov/statfacts/html/lungb.html

Bryant AK, Sankar K, Zhao L, Strohbehn GW, Elliott D, Moghanaki D, et al. De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer. Eur J Cancer. 2022;171:55–63. https://doi.org/10.1016/j.ejca.2022.04.033.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kartolo A, Shah H, Hopman W, As F, Wheatley-Price P, Robinson A. Consolidative durvalumab outcomes in stage III non-small cell lung cancer in a multi-centre study. Cancer Treat Res Commun. 2021;29: 100496. https://doi.org/10.1016/j.ctarc.2021.100496.

Article  Google Scholar 

Jazieh K, Gad M, Saad A, Wei W, Pennell N. Tumor PD-L1 expression is associated with outcomes in stage III non-small cell lung cancer (NSCLC) patients treated with consolidation durvalumab. Transl Lung Cancer Res. 2021;10:3071–8. https://doi.org/10.21037/tlcr-21-249.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Faehling M, Schumann C, Christopoulos P, Hoffknecht P, Alt J, Horn M, et al. Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP). Lung Cancer. 2020;150:114–22. https://doi.org/10.1016/j.lungcan.2020.10.006.

Article  PubMed  Google Scholar 

Paz-Ares L, Spira A, Raben D, Planchard D, Cho BC, Özgüroğlu M, et al. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Ann Oncol. 2020;31(6):798–806. https://doi.org/10.1016/j.annonc.2020.03.287.

Article  PubMed  CAS  Google Scholar 

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Nonsmall Cell Lung Cancer V.7.2024. United States: National Comprehensive Cancer Network, Inc; 2024 [accessed 17 June 2024]. Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

Delasos L, Wei W, Hassan KA, Pennell NA, Patil P, Stevenson J. Clinical Outcomes with pembrolizumab-based therapies in recurrent/refractory NSCLC after chemoradiation and consolidative durvalumab. Clin Lung Cancer. 2023;24(6):e205–13. https://doi.org/10.1016/j.cllc.2023.04.008.

Article  PubMed  CAS  Google Scholar 

Lu S, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, et al. Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. N Engl J Med. 2024;391(7):585–97. https://doi.org/10.1056/NEJMoa2402614.

Article  PubMed  CAS  Google Scholar